Clinical trial
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00075959 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00075959 |
|---|---|
| Title | Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke |
| Official title | CHANT (Cerebral Hemorrhage And NXY Treatment) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients With Acute Intracerebral Hemorrhage (ICH) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intracerebral Hemorrhage |
| Intervention type | Drug |
| Interventions | NXY-059 |
| Enrollment | 600 |
| Start date | Aug 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Jan 14, 2004 |
| Last update posted | Jan 4, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: